Barbara Troupin
Directeur/Membre du Conseil chez EQUILLIUM, INC.
Fortune : - $ au 31/05/2024
Postes actifs de Barbara Troupin
Sociétés | Poste | Début | Fin |
---|---|---|---|
EQUILLIUM, INC. | Directeur/Membre du Conseil | 01/02/2022 | - |
Independent Dir/Board Member | 01/02/2022 | - |
Historique de carrière de Barbara Troupin
Anciens postes connus de Barbara Troupin
Sociétés | Poste | Début | Fin |
---|---|---|---|
MYOKARDIA, INC. | Corporate Officer/Principal | 01/04/2020 | 01/03/2021 |
Erx Pharmaceuticals, Inc. | Directeur Technique/Scientifique/R&D | 01/12/2018 | 01/12/2019 |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Directeur Technique/Scientifique/R&D | 03/10/2016 | 01/07/2018 |
Conseiller Juridique Général | 03/10/2016 | 01/07/2018 | |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 15/12/2014 | 31/05/2016 |
VIVUS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2006 | 01/08/2014 |
Formation de Barbara Troupin
Perelman School of Medicine | Doctorate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
University of California San Diego | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Canada | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
EQUILLIUM, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
VIVUS, Inc.
VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
MyoKardia, Inc.
MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Erx Pharmaceuticals, Inc. |
- Bourse
- Insiders
- Barbara Troupin
- Expérience